ZLZhe Liu

Zhe Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhe Liu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Wenying Yu

    State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China

    3 shared publications
  • Huan Wang

    School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, China

    2 shared publications
  • Lingnan Guan

    School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, China

    2 shared publications
  • Maode Lai

    Research Unit of Intelligence Classification of Tumor Pathology and Precision Therapy, Chinese Academy of Medical Sciences (2019RU042) & Zhejiang University School of Medicine, Hangzhou 310058, China

    2 shared publications
  • Chong Lai

    Department of Urology, First Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China

    1 shared publication
  • Guoping Sun

    Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

    1 shared publication

Latest Publications

  • Open Access

    The Neuroprotective Role of a Caspase-1 Inhibitor Against Apoptosis via Inhibition of Glial Hyperactivation in a Mouse Model of Epilepsy

    by Hui Cai, Xinran Xu, Xuerui Zhuo, Zhe Liu, Hao Liu, Yiming Sun

    Background: Epilepsy is a central nervous system disorder characterized by abnormal neuronal discharges in the brain. The purpose of this study was to investigate the protective effects of a caspase-1 inhibitor on glial hyperactivation and neuronal apoptosis in epilepsy. Methods: A pilocarpine-induced status epilepticus (SE) mouse model was established. Belnacasan (VX765), a caspase-1 inhibitor, was administered intraperitoneally. ELISA was used to detect inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α) in peripheral blood. Immunohistochemistry and transmission electron microscopy were used to evaluate glial activation and neuronal damage in the hippocampus. Western blotting was performed to detect caspase-1 and Gasdermin D N-terminal (GSDMD-N) expression. In vitro, primary glial cells were stimulated with lipopolysaccharide (LPS), and the effects of glial conditioned medium on HT22 neuronal apoptosis were assessed using cell counting kit-8 (CCK-8) and flow cytometry. Results: In vivo experiments showed that, as epilepsy progressed, the levels of pro-inflammatory cytokines IL-1β and IL-6 in peripheral blood were significantly increased, consistent with findings in patients with epilepsy. At 21 days after epilepsy induction, the numbers of hyperactivated microglia and astrocytes increased significantly and exhibited activation-related features such as organelle swelling, whereas neuronal numbers were markedly reduced and displayed cytological features of apoptosis. VX765 significantly alleviated seizure frequency and severity in epileptic mice and attenuated peripheral blood levels of IL-1β and IL-6, hippocampal caspase-1 activity, glial hyperactivation, and neuronal apoptosis. In vitro experiments demonstrated that glial conditioned medium (CMG) promoted apoptosis of HT22 neurons by regulating Bcl-2-associated X protein (Bax) and B-cell lymphoma 2 (Bcl-2) expression, whereas VX765 alleviated HT22 neuronal apoptosis by inhibiting the secretion of inflammatory factors from glial cells. Conclusions: These results indicate that inhibiting glial cell hyperactivation and neuroinflammation via caspase-1 inhibition may represent a potential therapeutic strategy for epilepsy.

  • Open Access

    Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer

    by Zhe Liu, Liang Ma, Yiming Sun, Wenying Yu, Xue Wang

    Lung cancer is one of the most aggressive cancers with poor prognosis and high resistance rate. The family of signal transducer and activator of transcriptions (STATs) appears to modulate resistance in non-small cell lung cancer (NSCLC). In this work, we demonstrated that STAT3/ZEB1 is a critical axis in gefitinib resistance. STAT3-targeted inhibition therefore is a new potential therapeutic strategy for gefitinib resistance in lung cancer. Our small molecule screening identified a relatively specific STAT3-targeted inhibitor, LL1. Pharmacological and biochemical studies indicated that LL1 block the activation of STAT3 via inhibiting its phosphorylation. Further in vitro and in vivo studies elucidated that LL1 sensitizes the resistance cells to gefitinib through depleting STAT3 activity and blocking STAT3/ZEB1 signaling pathways. Little toxicity of LL1 was observed in animal models. All these favorable results indicated that LL1 is a chemotherapeutic adjuvant for gefitinib resistance in NSCLC.


  • Open Access

    Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo

    by Zhe Liu, Xianmin Ge, Yuchen Gu, Yingying Huang, Hao Liu, Meiling Yu, Yamin Liu


  • Open Access

    LL1, a novel and highly selective STAT3 inhibitor, displays anti‐colorectal cancer activities in vitro and in vivo

    by Zhe Liu, Huan Wang, Lingnan Guan, Chong Lai, Wenying Yu, Maode Lai

    Background and Purpose: Signal transducer and activator of transcription 3 (STAT3) factor is associated with the development and progression of numerous types of human cancer. STAT3 activation is involved in metastasis. However, no STAT3 inhibitor has been used therapeutically. Hence, we syntheised a novel, potent and small‐molecule inhibitor of STAT3, LL1, and studied its antitumour effects and investigated its mechanism of action in two tumour models.Experimental Approach: Using structure‐based drug design method, based on the crystal structure of STAT3 protein, we identified a potent STAT3 inhibitor (LL1) targeting STAT3 SH2 domain and characterized its therapeutic properties and potential toxicity in vitro and in vivo using the MTT assay, colony formation assay, histological, immunohistochemical, flow cytometric analysis, and tumour xenograft model.Key Results: LL1 is highly selective among STATs family members and specifically inhibits phosphorylation of STAT3 Tyr‐705 site, blocking the whole transmission process of STAT3 signalling. LL1 inhibited proliferation, colony formation, migration, and invasion of colonic cell lines. STAT3 is orally available to animals and suppresses tumour growth and metastasis in a dosage level compatible to clinical applications. Importantly, it does not cause significant toxicity at several times the effective dose.Conclusions and Implications: LL1 inhibits tumour growth and metastasis by blocking STAT3 signalling pathway. LL1 could be a promising therapeutic drug candidate for colorectal cancer by inhibiting the STAT3 activation.


  • Open Access

    Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro

    by Zhen-Yuan Gao, Zhe Liu, Ming-Hong Bi, Jing-Jing Zhang, Zheng-Quan Han, Xiao Han, Hong-Ya Wang, Guo-Ping Sun, Hao Liu

    Breast cancer is the most commonly occurring cancer and second leading cause of mortality in women. Metformin is a widely prescribed anti-hyperglycemic drug, which is emerging as a potential cancer preventative and treatment agent. However, the mechanisms underlying the suppressive effects of metformin on cancer cell growth and the induction of cancer cell apoptosis are not fully elucidated. The present study aimed to identify the pathways regulated by metformin in two breast cancer cell lines, MDA‑MB‑231 and MDA‑MB‑435. Cells were treated with various concentrations of metformin and then evaluated with respect to viability, proliferation, adenosine triphosphate (ATP) and reactive oxygen species (ROS) levels, mitochondrial membrane potential (∆ψm), and the expression of anti‑ and pro‑apoptotic proteins. Metformin caused apoptosis in a concentration‑ and time‑dependent manner, and decreased cell viability and ATP production. Furthermore, metformin induced the generation of ROS and decreased the ∆ψm. Moreover, metformin downregulated the expression of the anti‑apoptotic proteins B‑cell lymphoma 2 (BCL‑2) and myeloid cell leukemia‑1, and upregulated the expression of the pro‑apoptotic BCL‑2‑associated X protein in MDA‑MB‑231 cells. These results demonstrate that the apoptotic and cytotoxic effects of metformin on breast cancer cells are mediated by the intrinsic mitochondria-mediated apoptosis pathway.